Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TERAZOL 3 is a vaginal antifungal cream approved by the FDA in 1991 for the treatment of vulvovaginal candidiasis. The product is a small-molecule azole antifungal administered topically as a 3-day vaginal cream regimen. It remains a standard therapeutic option in the OTC and prescription antifungal market.
With LOE approaching and moderate competitive pressure (30), the brand team is likely focused on cost-containment and defensive positioning rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TERAZOL 3 offers limited career growth opportunity given its LOE-approaching lifecycle and zero linked job openings. Roles are primarily defensive and focused on protecting market share in an increasingly commoditized segment rather than driving innovation or expansion.
Worked on TERAZOL 3 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.